Patents Assigned to Celularity, Inc.
-
Publication number: 20210032596Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.Type: ApplicationFiled: March 12, 2020Publication date: February 4, 2021Applicant: Celularity, Inc.Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
-
Publication number: 20210002606Abstract: Provided herein are methods of culturing cells using microcarriers that include extracellular matrix (ECM).Type: ApplicationFiled: September 18, 2020Publication date: January 7, 2021Applicant: Celularity Inc.Inventors: Robert J. HARIRI, Mohit BHATIA
-
Publication number: 20200397830Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.Type: ApplicationFiled: January 24, 2020Publication date: December 24, 2020Applicant: CELULARITY, INC.Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
-
Publication number: 20200330516Abstract: Provided herein are methods of producing natural killer (NK) cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and the NK cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and the NK cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.Type: ApplicationFiled: May 18, 2020Publication date: October 22, 2020Applicant: Celularity Inc.Inventors: Brian MURPHY, Vanessa VOSKINARIAN-BERSE, Andrea NORDBERG, Keith WILSON, Lin KANG
-
Publication number: 20200246385Abstract: Provided herein are micro-organoids, referred to herein as Functional Physiological Units (FPUs), that are capable of replacing or augmenting one or more physiological functions in an individual, which are useful in the treatment of individuals lacking, or suffering a deficit in, said physiological function.Type: ApplicationFiled: April 21, 2020Publication date: August 6, 2020Applicant: Celularity Inc.Inventors: Robert J. HARIRI, Mohit BHATIA, Jia-Lun WANG, Wolfgang HOFGARTNER, Qian YE
-
Publication number: 20200246393Abstract: Provided herein are methods of suppressing the growth or proliferation of tumor cells and methods of treating individuals having tumor cells using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer (PINK) cells, combined natural killer (NK) cells, or combinations thereof, in combination with an antibody (e.g., anti-disialoganglioside (anti-GD2) antibody). Also provided herein are compositions comprising placental perfusate, placental perfusate cells, PINK cells, combined NK cells, or combinations thereof, in combination with an antibody (e.g., anti-GD2 antibody).Type: ApplicationFiled: September 27, 2018Publication date: August 6, 2020Applicant: CELULARITY, INC.Inventors: Xiaokui ZHANG, Lin KANG, Robert J. HARIRI
-
Publication number: 20200188446Abstract: A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.Type: ApplicationFiled: February 24, 2020Publication date: June 18, 2020Applicant: CELULARITY, INC.Inventor: Robert J. Hariri
-
Publication number: 20200138872Abstract: An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.Type: ApplicationFiled: December 16, 2019Publication date: May 7, 2020Applicant: CELULARITY, INC.Inventor: Naoko TAKEBE
-
Patent number: 10590381Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.Type: GrantFiled: July 28, 2017Date of Patent: March 17, 2020Assignee: Celularity, Inc.Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
-
Patent number: 10564087Abstract: Provided are methods for quantifying and/or detecting sub-visible particulates in cell cultures. Specifically, the methods comprise a step of breaking down, e.g., lysing, cells in a cell culture. The methods can further comprising filtering the cell culture through a filter. Further provided are methods of quantifying sub-visible particulates that do not pass through the filter using a microscope.Type: GrantFiled: September 11, 2015Date of Patent: February 18, 2020Assignee: Celularity, Inc.Inventors: Lauren M. Depalma, Daniel Dewitt, Li Ren
-
Publication number: 20200048603Abstract: Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34+CD45? stem cells from placenta.Type: ApplicationFiled: October 18, 2019Publication date: February 13, 2020Applicant: CELULARITY, INC.Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Marian Pereira, Sascha Dawn Abramson, Kristen S. Labazzo
-
Patent number: 10548926Abstract: An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.Type: GrantFiled: March 11, 2016Date of Patent: February 4, 2020Assignee: CELULARITY, INC.Inventor: Naoko Takebe
-
Publication number: 20200023015Abstract: Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™).Type: ApplicationFiled: August 5, 2019Publication date: January 23, 2020Applicant: CELULARITY, INC.Inventors: Uri Herzberg, Jodi P. Gurney
-
Publication number: 20200009199Abstract: The present invention provides cytotherapeutic units comprising predetermined numbers of selected types of potent cells. Assurance of the nature and identities of such cells is achieved through assay and certification of said numbers and identities. Therapeutic modalities are provided. Libraries of cell preparations with assayed and preferably certified populations are preferred and the preparation of cell preparations tailored to specific patients or disease states are provided.Type: ApplicationFiled: August 5, 2019Publication date: January 9, 2020Applicant: CELULARITY, INC.Inventor: Robert J. Hariri
-
Publication number: 20190388478Abstract: Provided herein are methods of using human placental stem cells in the treatment of subjects having acute kidney injury (AKI).Type: ApplicationFiled: August 14, 2019Publication date: December 26, 2019Applicant: CELULARITY, INC.Inventors: Steven A. Fischkoff, Hong-Jung Chen
-
Publication number: 20190376027Abstract: The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.Type: ApplicationFiled: August 22, 2019Publication date: December 12, 2019Applicant: Celularity, Inc.Inventors: James W. Edinger, Mohammad Heidaran, Wolfgang Hofgartner
-
Patent number: 10494607Abstract: Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34+CD45? stem cells from placenta.Type: GrantFiled: February 12, 2008Date of Patent: December 3, 2019Assignee: CELULARITY, INC.Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Marian Pereira, Sascha Dawn Abramson, Kristen S. Labazzo
-
Publication number: 20190330592Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.Type: ApplicationFiled: July 3, 2019Publication date: October 31, 2019Applicant: Celularity, Inc.Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
-
Publication number: 20190321413Abstract: The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.Type: ApplicationFiled: May 30, 2019Publication date: October 24, 2019Applicant: CELULARITY, INC.Inventors: Mohammad A. Heidaran, Robert J. Hariri, Kristine Erickson Johnson
-
Publication number: 20190314424Abstract: Provided herein are methods of using tissue culture plastic-adherent placental adherent cells, e.g. placental stem cells, referred to herein as placental adherent cells, to treat lymphedema and lymphedema-related disorders.Type: ApplicationFiled: December 6, 2017Publication date: October 17, 2019Applicant: CELULARITY, INC.Inventors: Robert J. Hariri, Shuyang He